In this episode, Dr. Stader and Dr. Bradley summarize and offer key insights for the following Coaches Top 5 picks, discussing extended-release injectable buprenorphine versus sublingual, mortality association with benzodiazepine and opioid agonist co-prescribing, and more!
Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements, Published in JAMA, July 2024
Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use A Post Hoc Analysis of a Randomized Clinical Trial, Published in JAMA, June 2024
Empowered Relief, cognitive behavioral therapy, and health education for people with chronic pain: a comparison of outcomes at 6-month Follow-up for a randomized controlled trial, Published in Pain Reports, Jan 2024
The association between benzodiazepine co-prescription, opioid agonist treatment and mortality: a systematic review, Published in BMC Psychiatry, October 2024
Rapid Initiation of Injection Naltrexone for Opioid Use Disorder, Published by JAMA, May 2024
